US2018214514A1PendingUtilityA1

Compositions and Treatments of Metabolic Disorders Using FGF Binding Protein 3

61
Assignee: UNIV GEORGETOWNPriority: Mar 14, 2013Filed: Oct 16, 2017Published: Aug 2, 2018
Est. expiryMar 14, 2033(~6.6 yrs left)· nominal 20-yr term from priority
Inventors:Anton Wellstein
A61K 38/1709
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to methods of treating a metabolic disorder in a subject, the method comprising administering fibroblast growth factor binding protein 3 (FGFBP3) or a variant thereof to a subject in need of treatment of a metabolic disorder.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating a metabolic disorder in a subject, the method comprising administering fibroblast growth factor binding protein 3 (FGFBP3) to a subject in need of treatment of a metabolic disorder. 
     
     
         2 . The method of  claim 1 , wherein the metabolic disorder is diabetes. 
     
     
         3 . The method of  claim 1 , wherein the metabolic disorder is obesity. 
     
     
         4 . The method of  claim 1 , wherein the metabolic disorder is hyperglycemia. 
     
     
         5 . The method of  claim 1 , wherein the metabolic disorder is glycogen metabolism. 
     
     
         6 . A method of lowering blood glucose levels in a subject, the method comprising administering fibroblast growth factor binding protein 3 (FGFBP3) to a subject in need of lowering of blood glucose levels. 
     
     
         7 . A method of lowering a subject's body weight, the method comprising administering fibroblast growth factor binding protein 3 (FGFBP3) to a subject in need of lowering its body weight. 
     
     
         8 . A method of regulating at least one component of postprandial metabolism in a subject, the method comprising administering fibroblast growth factor binding protein 3 (FGFBP3) to a subject in need of regulation of postprandial metabolism. 
     
     
         9 . The method of  claim 8 , wherein the at least one component of postprandial metabolism is hepatic glycogen synthesis. 
     
     
         10 . The method of  claim 8 , wherein the at least one component of postprandial metabolism is protein synthesis. 
     
     
         11 . The method of  claim 8 , wherein the at least one component of postprandial metabolism is clearance of plasma glucose. 
     
     
         12 . The method  claim 8 , wherein hepatic triglyceride levels are not affected. 
     
     
         13 . A method of increasing protein synthesis in a cell, the method comprising contacting the cell with fibroblast growth factor binding protein 3 (FGFBP3) in an amount sufficient to stimulate protein production in the cell. 
     
     
         14 . The method of  claim 13 , wherein the cell is in cell culture. 
     
     
         15 . The method of  claim 13 , wherein the cell is part of an organism. 
     
     
         16 . A method of treating a metabolic disorder in a subject, the method comprising administering a complex of fibroblast growth factor 19 (FGF19) and fibroblast growth factor binding protein 3 (FGFBP3) to a subject in need of treatment of a metabolic disorder. 
     
     
         17 . The method of  claim 16 , wherein the metabolic disorder is diabetes. 
     
     
         18 . The method of  claim 16 , wherein the metabolic disorder is obesity. 
     
     
         19 . The method of  claim 16 , wherein the metabolic disorder is hyperglycemia. 
     
     
         20 . The method of  claim 16 , wherein the metabolic disorder is glycogen metabolism.

Join the waitlist — get patent alerts

Track US2018214514A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.